Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ghanei, M. Hosseini, A. Ani, M. A. Abbasi, J. Aslani (Tehran, Islamic Republic Of Iran). Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?. Eur Respir J 2009; 34: Suppl. 53, 1995

Member's Comments

No comment yet.

Related content which might interest you: Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 How often do asthma patients claim prescribed therapy? Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS Year: 2017 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204 Year: 2014 Lack of clinically relevant differences between combination therapy and monotherapy in COPD Source: Eur Respir J 2014; 43: 1204-1205 Year: 2014 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Effectiveness of combined therapy in patients with brittle asthma Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002